AstraZeneca PLC (AZNCF)
AstraZeneca PLC operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Cambridge, GB. The stock last traded at $189.90, down 1.35% on the session, giving a market capitalisation of $294.40B. On trailing twelve-month figures it carries a trailing P/E of 28.86, a net margin of 17.5%. Its beta of 0.19 implies it has historically moved less than the broad market.
AstraZeneca PLC functions as a global biopharmaceutical enterprise, committed to the entire process of pharmaceutical innovation, spanning from the initial discovery and development stages to the manufacturing and market introduction of its prescription medications. The company boasts a comprehensive portfolio of drugs addressing a diverse array of therapeutic areas. This encompasses a robust selection for oncology, featuring key treatments such as Calquence, Enhertu, and Tagrisso, alongside vital therapies for cardiovascular, renal, and metabolic conditions, including Farxiga/Forxiga and Brilinta/Brilique. Its offerings further extend to impactful medications for respiratory and immunological ailments like Symbicort and Fasenra, as well as specialized remedies for rare diseases, notably Soliris and Ultomiris. Beyond these primary categories, AstraZeneca's product range includes solutions for infectious diseases, such as Synagis for RSV and the COVID-19 vaccines Vaxzevria and Evusheld, in addition to treatments for neurological disorders like Seroquel and gastrointestinal issues epitomized by Nexium. AstraZeneca distributes its pharmaceuticals to medical practitioners in both primary and specialty care settings worldwide, utilizing an extensive network of distributors and local offices throughout the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. The company actively engages in strategic alliances to propel its research and development efforts. Significant collaborations include agreements with Regeneron Pharmaceuticals, Inc., for the creation of small molecule medicines targeting obesity; Neurimmune AG, for developing and commercializing NI006; Ionis Pharmaceuticals, Inc., to advance eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH, for co-discovering novel small molecules for hematological cancers; and Sierra Oncology, Inc., regarding the development and commercialization of AZD5153. Founded in 1992, the company, formerly known as Zeneca Group PLC, rebranded as AstraZeneca PLC in April 1999 and is headquartered in Cambridge, United Kingdom.
AstraZeneca PLC is most often compared with the following Healthcare names: